High expression of FOXC2 was a strong predictor of clinical recurrence and cancer specific survival among Gleason score 7 prostate cancer patients in our series, along with the EN‐switch and Gleason grade groups 3 versus 2. This evidence concerns the gene FOXC2 and cancer.